What Makes BioCryst Pharmaceuticals (BCRX) a Strong Momentum Stock: Buy Now?
Does BioCryst Pharmaceuticals (BCRX) have what it takes to be a top stock pick for momentum investors? Lets find out.…
8,838€
0,20%
Echtzeit-Aktienkurs BioCryst Pharmaceuticals Inc.
Bid:
Ask:
Nachrichten zur BioCryst Pharmaceuticals Inc. Aktie
BioCryst Pharmaceuticals (BCRX): Profitabilitätsaussichten für 2025 lösen Ausbruch auf ein 52-Wochenhoch aus!
BioCryst Pharmaceuticals Inc. (BCRX) (i.) hat sich auf seltene Krankheiten spezialisiert. Das Hauptprodukt des Unternehmens ist ORLADEYO (Berotralstat), ein einmal…
BioCryst Pharmaceuticals (BCRX): Anleger honorieren Prognoseanhebung mit Kursanstieg auf ein 52-Wochenhoch!
BioCryst Pharmaceuticals Inc. (BCRX) (i.) hat am 05. Mai die Erwartungen der Experten mit den vorgelegten Zahlen für das 1.…
How BioCryst Pharmaceuticals, Inc. (BCRX) Stock Stands Out in a Strong Industry
BioCryst (BCRX) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as…
Why BioCryst Pharmaceuticals Stock Tumbled by 10% Today
Investors clearly werent in a forgiving mood on Monday when it came to BioCryst Pharmaceuticals (NASDAQ: BCRX) stock. After the…
BioCryst Pharmaceuticals (BCRX) Q4 2024 Earnings Call Transcript
BCRX earnings call for the period ending December 31, 2024.…
BioCryst Pharmaceuticals, Inc. (BCRX) Q4 2024 Earnings Call Transcript
…
BioCryst Pharmaceuticals (BCRX) May Report Negative Earnings: Know the Trend Ahead of Next Weeks Release
BioCryst (BCRX) doesnt possess the right combination of the two key ingredients for a likely earnings beat in its upcoming…
BioCryst Pharmaceuticals: Seasoned Blockbuster Makes It A Buy
…
BioCryst Launches ORLADEYO® (berotralstat) in Ireland
RESEARCH TRIANGLE PARK, N.C., Nov. 18, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the Health…
BioCryst Pharmaceuticals (BCRX) Q3 2024 Earnings Call Transcript
BCRX earnings call for the period ending September 30, 2024.…
BioCryst Pharmaceuticals, Inc. (BCRX) Q3 2024 Earnings Call Transcript
…
BioCryst Pharmaceuticals, Inc. 2024 Q3 - Results - Earnings Call Presentation
…
BioCryst Pharmaceuticals awarded $69M influenza treatment contract from U.S. HHS
…
BioCryst Presents New ORLADEYO® (berotralstat) Data at 7th Bradykinin Symposium
RESEARCH TRIANGLE PARK, N.C., Sept. 06, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced the presentation of…
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
RESEARCH TRIANGLE PARK, N.C., Sept. 04, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that…
BioCryst to Present at Upcoming Investor Conferences
RESEARCH TRIANGLE PARK, N.C., Aug. 22, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the…
BioCryst Pharmaceuticals (BCRX) Q2 2024 Earnings Call Transcript
BCRX earnings call for the period ending June 30, 2024.…
BioCryst Pharmaceuticals, Inc. (BCRX) Q2 2024 Earnings Call Transcript
…
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
RESEARCH TRIANGLE PARK, N.C., Aug. 02, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that…
BioCryst to Report Second Quarter 2024 Financial Results on August 5
RESEARCH TRIANGLE PARK, N.C., July 22, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the…
Betting On BioCryst Pharmaceuticals: Orladeyos Success Fuels Future Prospects
…
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
RESEARCH TRIANGLE PARK, N.C., July 02, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that…
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
RESEARCH TRIANGLE PARK, N.C., June 04, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that…
ORLADEYO® (berotralstat) Approved in Mexico
RESEARCH TRIANGLE PARK, N.C., May 13, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the…
BioCryst Pharmaceuticals (BCRX) Q1 2024 Earnings Call Transcript
BCRX earnings call for the period ending March 31, 2024.…
BioCryst Pharmaceuticals, Inc. (BCRX) Q1 2024 Earnings Call Transcript
…
BioCryst Pharmaceuticals, Inc. 2024 Q1 - Results - Earnings Call Presentation
…
BioCryst Pharmaceuticals (BCRX) Reports Q1 Loss, Tops Revenue Estimates
BioCryst (BCRX) delivered earnings and revenue surprises of 26.09% and 8.37%, respectively, for the quarter ended March 2024. Do the…
BioCryst Announces Approval of ORLADEYO® (berotralstat) by the Brazilian Health Regulatory Agency
RESEARCH TRIANGLE PARK, N.C., April 17, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the…
BioCryst Pharmaceuticals (BCRX) Q4 2023 Earnings Call Transcript
BCRX earnings call for the period ending December 31, 2023.…
BioCryst Pharmaceuticals, Inc. (BCRX) Q4 2023 Earnings Call Transcript
…